Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network.

Ear and hearing·2026
Same author

Prevalence of diabetes mellitus in long-term cancer survivors treated with craniospinal irradiation.

Journal of the Endocrine Society·2026
Same author

Transition to adulthood in Duchenne Muscular Dystrophy: a systematic review with narrative synthesis on health systems, policies, and the role of health care providers.

Frontiers in public health·2026
Same author

Exploring and Overcoming Challenges for Efficient Audiological Testing in Children Under 5 Years of Age-Screening with Otoacoustic Emissions.

Audiology research·2026
Same author

Beyond the interferon score: neurofilament light chain and glial fibrillary acidic protein capture immune-mediated neuroinjury and response to JAK inhibition in Aicardi-Goutières syndrome.

Frontiers in immunology·2026
Same author

Heart Disease in Survivors of Childhood Cancer: Data From the German Childhood Cancer Registry and Statutory Health Insurance Carriers (the VersKiK Study).

Deutsches Arzteblatt international·2026

Related Experiment Video

Updated: May 10, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Understanding platinum-induced ototoxicity.

Thorsten Langer1, Antoinette am Zehnhoff-Dinnesen, Susanne Radtke

  • 1LESS Center, University Hospital for Children and Adolescents, Department for Pediatric Oncology and Immunology, Loschgestrasse 15, 91054 Erlangen, Germany.

Trends in Pharmacological Sciences
|June 18, 2013
PubMed
Summary
This summary is machine-generated.

Platinum chemotherapy drugs improve childhood cancer survival but cause significant ototoxicity. Research focuses on reducing this hearing damage without affecting cancer treatment efficacy.

Keywords:
adverse effectshigh frequency audiometryorganoplatinum compoundspharmacogeneticspreventionrisk factors

More Related Videos

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

Related Experiment Videos

Last Updated: May 10, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

Area of Science:

  • Oncology
  • Pharmacology
  • Ototoxicology

Background:

  • Childhood cancer survival rates are high in developed countries due to advanced therapies.
  • Platinum drugs (cisplatin, carboplatin) are crucial for childhood cancer treatment.
  • Ototoxicity affects over 60% of pediatric patients receiving platinum chemotherapy, impacting quality of life.

Purpose of the Study:

  • To review the incidence, presentation, and diagnosis of platinum-induced ototoxicity in children.
  • To discuss genetic and non-genetic risk factors for platinum ototoxicity.
  • To summarize recent advancements in preventing platinum ototoxicity in pediatric cancer patients.

Main Methods:

  • Literature review of studies on platinum ototoxicity in childhood cancer.
  • Analysis of clinical presentation, diagnostic methods, and risk factors.
  • Synthesis of current strategies for ototoxicity prevention.

Main Results:

  • Platinum chemotherapy, while effective, leads to ototoxicity in a majority of pediatric patients.
  • Ototoxicity can have severe, long-term effects on a child's quality of life.
  • Identifying risk factors is key to predicting and potentially mitigating ototoxicity.

Conclusions:

  • Reducing platinum-induced ototoxicity is a critical goal in pediatric oncology.
  • Further research into prevention strategies is essential to preserve hearing in childhood cancer survivors.
  • Balancing antitumor efficacy with reduced ototoxicity is paramount for improving patient outcomes.